Thyroid neoplasia in children

Current Opinion in Pediatrics

Volumn 9, Issue 4, 1997, Pages 413-418

  Zimmerman, Donald ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; CANCER RISK; CHERNOBYL ACCIDENT; CHILDHOOD CANCER; GENE MUTATION; HUMAN; ONCOGENE RET; PRIORITY JOURNAL; PROTO ONCOGENE; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; REMISSION; SHORT SURVEY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; TUMOR SUPPRESSOR GENE;

EID: 0030804349     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199708000-00017     Document Type: Short Survey

References (68)

1. Fukunaga FH, Yatani R: Geographical pathology of occult thyroid carcinomas. Cancer 1975, 36:1095-1099.
2. Harach HR, Franssila KO, Wasenius V-M: Occult papillary carcinoma of the thyroid: a 'normal' finding in Finland. A systematic autopsy study. Cancer 1985, 56:531-538.
3. Franssila KO, Harach H: Occult papillary carcinoma of the thyroid in children and young adults: a systematic autopsy study in Finland. Cancer 1986, 558:715-719.
4. Parkin DM, Muir C, Whelan SL, Gao Y-T, Ferlay J, Powell J: Cancer incidence in five continents. IARC Sci Publ 1992, VI(120).
5. Harach HR, Williams ED: Childhood thyroid cancer in England and Wales. Br J Cancer 1995, 72:777-783. This study provides a very recent estimate of the incidence of various types of thyroid cancer in England and Wales. A large proportion of the pathologic material was carefully reexamined by the investigators, who observed distinctive histology in tumors in children younger than 10 years of age.
6. Zimmerman D, Hay IH, Gough IR, Goellner JR, Ryan JJ, Grant CS, McConahey WM: Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one Institution during three decades. Surgery 1988, 104:1157-1166.
7. Ezaki H, Ebihara S, Fujimoto Y, Iida F, Ito K, Kuma K, Izuo M, Makiuli M, Oyamada H, Matoba N: Analysis of thyroid carcinoma based on material registered in Japan during 1977-1986 with special reference to predominance of papillary type. Cancer 1992, 70:808-814.
8. Schlumberger M, De Vathaire F, Travagli JP, Vassal G, Lemerle J, Parmentier C, Tubiana M: Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Endocrinol Metab 1987, 65:1088-1094.
9. Zimmerman D, Hay IH, Bergstralh E: Papillary thyroid carcinoma in children. In Treatment of Thyroid Cancer in Childhood DOE/EH-0406. Edited by Robbins J. Washington, DC: US Department of Energy; 1994:3-10.
10. Hassoun AAK, Hay ID, Goellner JR, Zimmerman D: Insular thyroid carcinoma in adolescents: a potentially lethal endocrine malignancy. Cancer 1997, 79:1044-1048.
11. Kotiloglu E, Kale G, Senocak ME: Follicular thyroid carcinoma with a predominant insular component. Tumori 1996, 81:296-298.
12. Mauras N, Zimmerman D, Goellner JR: Hashimoto thyroiditis associated with thyroid cancer in adolescent patients. J Pediatr 1985, 106:895-898.
13. Siddiqui AR, Karanauskas S: Hurthle cell carcinoma in an autonomous thyroid nodule in an adolescent. Pediatr Radiol 1995, 25:568-569.
14. Kazakov VS, Dimidchik EP, Astakhova LN: Thyroid cancer after Chernobyl. Nature 1992, 359:21.
15. Baverstock K, Egloff B, Pinchera A, Ruchti C, Williams D: Thyroid cancer after Chernobyl. Nature 1992, 359:21-22.
16. Nikiforov Y, Gnepp DR: Pediatric thyroid cancer after the Chernobyl disaster: pathomorphologic study of 84 cases (1991-2) from the Republic of Belarus. Cancer 1994, 74:748-766.
17. Dimidchik EP, Kazakov VS, Astokhova LN, Okeanov AE, Dimidchik YE: Thyroid cancer in children after the Chernobyl accident clinical and epidemiological evaluation of 251 cases in the Republic of Belarus. In Nagasaki Symposium Cherynobyl: Update and Future. Edited by Nagataki S. Amsterdam: Excerpta Medica, Elsevier Press; 1994:21-30.
18. Tronko N, Epstein Y, Olenaik V, Bofdanja T, Hkhtarey I, Gucko G, Kairo I, Sobolev B: Thyroid gland in children after the Chernobyl accident (yesterday and today). Nagasaki Symposium Chernobyl: Update and Future. Edited by Nagataki S. Amsterdam: Excerpta Medica, Elsevier Press; 1994:31-46.
19. Nikiforov Y, Gnepp DR, Fagin JA: Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab 1996, 81:9-14.
20. Sali D, Cardis E, Sztanyik L, Auvinen A, Bairakova A, Dontas N, Grosche B, Kerekes A, Kusic Z, Kusoglu C, et al.: Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Int J Cancer 1996, 67:343-352.
21. Mangano JJ: A post-Chernobyl rise in thyroid cancer in Connecticut, USA. Eur J Cancer Prev 1996, 5:75-81.
22. Likhtaren IA, Sobolev BG, Kairo IA: Thyroid cancer in the Ukraine. Nature 1995, 375:365.
23. Williams D: Thyroid cancer and the Chernobyl accident [editorial]. J Clin Endocrinol Metab 1996, 81:6-8.
24. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Borce JD Jr: Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995, 141:259-277.
25. Ivanov EP, Tolochko G, Lazare VS, Shuvaeva L: Child leukemia after Chernobyl. Nature 1993, 365:702.
26. Buglova EE, Kenigsberg JE, Sergeeva NV: Cancer risk estimation in Belarussian children due to thyroid irradiation as a consequence of the Chernobyl nuclear accident. Health Phys 1996, 71:45-49.
27. Dobyns BM, Sheline GE, Worman JB, Tompkins EA, McConahey WM, Becker DR: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974, 38:976-998.
28. Safa AM, Schumacher OP, Rodriguez-Anturez A: Long-term follow-up results in children and adolescents treated with radioactive-iodine (131I) for hyperthyroidism. N Engl J Med 1975, 292:167-171.
29. Holm L-E, Dahlquist I, Israelsson A, Lundell G: Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study. N Engl J Med 1980, 303:188-191.
30. Holm GE, Wiklund KE, Lundel GE: Thyroid cancer after diagnostic doses of iodine-131: a retrospective cohort study. J Natl Cancer Inst 1988, 80:1132-1138.
31. Duh Q-Y, Grossman RF: Thyroid growth factors, signal transduction pathways, and oncogenes. Surg Clin North Am 1995, 75:421-437.
32. Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, Filetti S, Svarez HG: Activating mutations of the TSH receptor in differentiated thyroid carcinomas. Oncogene 1995, 10:1907-1911. A possible role for mutations of the TSH receptor in the pathogenesis of thyroid cancers is described.
33. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVilard JA, Caillou B, Monier R, Rapoport B, Filetti S, Svarez HG: Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995, 80:1347-1351.
34. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantun F, Pachnis V: Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor RET. Nature 1994, 367:380-383.
35. Nakamura T, Ishizaka Y, Nagao M, Hara M, Ishikawa T: Expression of the RET proto-oncogene product in human normal and neoplastic tissues of neural crest origin. J Pathol 1994, 172:255-260.
36. Mulligan LM, Ponder BAJ: Genetic basis of endocrine disease: multiple endocrine neoplasia Type 2. J Clin Endocrinol Metab 1995, 80:1989-1995. A succinct review of MEN2 with a detailed discussioin of the relationship of specific RET mutations and disease phenotype.
37. Eng C: The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996, 335:943-951.
38. Cote GJ, Wohllk N, Evans D, Goepfert H, Gagel RF: RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab 1995, 9:609-630. This paper summarizes recent molecular biology findings that elucidate the pathogenesis of MTC and permit reliable family screening.
39. Worby CA, Vega QC, Zhao Y, Chao HHJ, Seasholtz AF, Dixon JE: Glial cell line-derived neurotrophic factor signals through the RET receptor and activates mitogen-activated protein kinase. J Biol Chem 1996, 271:23619-23622.
40. Santoro M, Carlomagno F, Romano A: Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383.
41. Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomen A, Roth J, Hertz PV: Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Cancer 1995, 76:479-489.
42. Jhiang SM, Fithian L, Weghorst CM, Clark OH, Falko JM, O'Dorisio TM, Mazzaferri EI: RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid 1996, 6:115-489.
43. 1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81:2006-2009.
44. Williams GH, Rooney S, Thomas GA, Cummins G, Williams ED: RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival nested material. Br J Cancer 1996, 71:585-589. This report analyzes the frequency with which chromosomal rearrangements involving portions of the RET protooncogene are involved in the pathogenesis of childhood papillary thyroid cancer.
45. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM: High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident Oncogens 1995, 10:2459-2467.
46. Fugazzda L, Pilotti S, Pinchera A, Vorontsoua TV, Mondellini P, Bongarzone I, Greco A, Astakhova L, Butti MG, Demidchik EP, et al.: Oncogene rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident Cancer Res 1995, 55:5617-5620.
47. Iro T, Seyama T, Iwamoto KS, Hayashi T, Mizuno T, Tsuyama N, Dohi K, Nakamura N, Akiyama M: In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res 1993, 53:2940-2943.
48. Pierotti MA, Santoro M, Jenkins RB, Sozzi G, Bongarzone I, Grieco M, Monzini N, Miozzo M, Herrmann MA, Fusco A, et al.: Characterization of an inversion on the long arm of chromosome 10 juxtaposing D105170 and ret and creating the oncogene sequence ret/ptc. Proc Natl Acad Sci U S A 1992, 89:1616-1620.
49. 3 are localized in chromosomal band 10q 11.2. Genes Chromosom Cancer 1994, 11:51-57.
50. Sozzi G, Bongarzone I, Miozzo M, Borello MG, Butti MG, Pilotti S, Della Porta G, Pierotti MA: A t(10,17) translocation creates the RET/ptc 2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosom Cancer 1994, 9:244-250.
51. Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I: Molecular and biochemical analysis of RET/PTC 4, a novel oncogene rearrangement between RET and ELE1 genes, in a post-Chernobylpapillary thyroid cancer. Oncogene 1996, 13:1093-1097.
52. Skinner MA, DeBenedetti MK, Moley JF, Norton JA, Wells SA Jr: Medullary thyroid carcinoma in children with multiple endocrine neoplasia type 2A and 2B. J Pediatr Surg 1996, 31:177-181. This study describes the high frequency of persistence and recurrence of papillary thyroid carcinoma in children and provides evidence that earlier surgery based on genetic diagnosis may improve the outcome.
53. Gill JR, Reyes-Mugica M, Iyengar S, Kidd KK, Touloukian RJ, Smith C, Keller MS, Genel M: Early presentation of metastatic medullary carcinoma in multiple endocrine neoplasia, type IIA: implications for therapy. J Pediatr 1996, 129:459-464.
54. Decker RA, Peacock ML, Borst MJ, Sweet JD, Thompson NW: Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995, 118:257-263.
55. Solomon BL, Wartofsky L, Burman KD: Current trends in the management of well-differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996, 81:333-339.
56. Hung W, Anderson KD, Chandra RS, Kapur SP, Patterson K, Randolph JG, August GP: Solitary thyroid nodules in 71 children and adolescents. J Pediatr Surg 1992, 27:1407-1409.
57. Raab SS, Silverman JF, Elsheikh TM, Thomas PA, Wakeds PE: Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy. Pediatrics 1995, 98:46-49. This study describes the use of FNA biopsy in the detection of carcinoma in childhood thyroid nodules.
58. Gharib H, Zimmerman D, Goettner JR, Bridley SM, LeBlanc SM: Fine needle aspiration biopsy: use in diagnosis and management of pediatric thyroid diseases. Endocr Pract 1995, 1:9-13.
59. Flannery TK, Kirkland JL, Copeland KC, Bertuch AA, Karaviti LP, Brandt ML: Papillary thyroid cancer: a pediatric perspective. Pediatrics 1996, 96:464-466.
60. Patwardhan N, Cataldo T, Braverman LE: Surgical management of the patient with papillary cancer. Surg Clin North Am 1995, 75:449-464.
61. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995, 80:1488-1492.
62. van Heerden JA, Grant CS, Gharib H, Hat VD, Ilstrup DM: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990, 212:395-400.
63. Tisell LE, Hansson G, Jansson S, Salander H: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986, 99:60-66.
64. Moley JF, Wells SA, Dilley WG, Tisell LE: Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993, 114:1090-1095.
65. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995, 118:1024-1030.
66. Colombo-Benkmann M, Hartkorn P, Elser H, Georgi P, Rave F, Buhr HJ, Senninger N, Herfarth C: Localization of recurrent medullary thyroid carcinoma: a comparative study [abstract]. Thyroid 1996, 6(suppl):594.
67. Magnani P, Paganelli G, Sungini C, Samuel A, Sudati F, Siccardi AG, Fazio F: Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma. Br J Cancer 1996, 74:825-831.
68. Juweid M, Sharkey RM, Behr T, Swayne LC, Herskovic T, Pereira M, Rubin AD, Hanley D, Dunn R, Siegel J, Goldenberg DM: Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996, 37:905-911.